346 related articles for article (PubMed ID: 28435907)
1. Modeling Tumor Clonal Evolution for Drug Combinations Design.
Zhao B; Hemann MT; Lauffenburger DA
Trends Cancer; 2016 Mar; 2(3):144-158. PubMed ID: 28435907
[TBL] [Abstract][Full Text] [Related]
2. Harnessing Tumor Evolution to Circumvent Resistance.
Pogrebniak KL; Curtis C
Trends Genet; 2018 Aug; 34(8):639-651. PubMed ID: 29903534
[TBL] [Abstract][Full Text] [Related]
3. Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.
Reinartz R; Wang S; Kebir S; Silver DJ; Wieland A; Zheng T; Küpper M; Rauschenbach L; Fimmers R; Shepherd TM; Trageser D; Till A; Schäfer N; Glas M; Hillmer AM; Cichon S; Smith AA; Pietsch T; Liu Y; Reynolds BA; Yachnis A; Pincus DW; Simon M; Brüstle O; Steindler DA; Scheffler B
Clin Cancer Res; 2017 Jan; 23(2):562-574. PubMed ID: 27521447
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
5. Drug-Resistant Cancer Treatment Strategies Based on the Dynamics of Clonal Evolution and PKPD Modeling of Drug Combinations.
Vakil V; Trappe W
IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(3):1603-1614. PubMed ID: 33326383
[TBL] [Abstract][Full Text] [Related]
6. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
McGranahan N; Swanton C
Cell; 2017 Feb; 168(4):613-628. PubMed ID: 28187284
[TBL] [Abstract][Full Text] [Related]
7. Engineering Multidimensional Evolutionary Forces to Combat Cancer.
McCoach CE; Bivona TG
Cancer Discov; 2019 May; 9(5):587-604. PubMed ID: 30992280
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
Venkatesan S; Swanton C; Taylor BS; Costello JF
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
[TBL] [Abstract][Full Text] [Related]
9. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
Gerlinger M; Swanton C
Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
[TBL] [Abstract][Full Text] [Related]
10. Translating insights into tumor evolution to clinical practice: promises and challenges.
Fittall MW; Van Loo P
Genome Med; 2019 Mar; 11(1):20. PubMed ID: 30925887
[TBL] [Abstract][Full Text] [Related]
11. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale.
Barber LJ; Davies MN; Gerlinger M
Curr Opin Genet Dev; 2015 Feb; 30():1-6. PubMed ID: 25555261
[TBL] [Abstract][Full Text] [Related]
12. Measuring Clonal Evolution in Cancer with Genomics.
Williams MJ; Sottoriva A; Graham TA
Annu Rev Genomics Hum Genet; 2019 Aug; 20():309-329. PubMed ID: 31059289
[TBL] [Abstract][Full Text] [Related]
13. Natural and Chemotherapy-Induced Clonal Evolution of Tumors.
Ibragimova MK; Tsyganov MM; Litviakov NV
Biochemistry (Mosc); 2017 Apr; 82(4):413-425. PubMed ID: 28371598
[TBL] [Abstract][Full Text] [Related]
14. Advances for studying clonal evolution in cancer.
Ding L; Raphael BJ; Chen F; Wendl MC
Cancer Lett; 2013 Nov; 340(2):212-9. PubMed ID: 23353056
[TBL] [Abstract][Full Text] [Related]
15. Clonal interactions in cancer: Integrating quantitative models with experimental and clinical data.
Lee ND; Kaveh K; Bozic I
Semin Cancer Biol; 2023 Jul; 92():61-73. PubMed ID: 37023969
[TBL] [Abstract][Full Text] [Related]
16. Preventing clonal evolutionary processes in cancer: Insights from mathematical models.
Rodriguez-Brenes IA; Wodarz D
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):8843-50. PubMed ID: 26195751
[TBL] [Abstract][Full Text] [Related]
17. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
Chisholm RH; Lorenzi T; Clairambault J
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
[TBL] [Abstract][Full Text] [Related]
18. Tumour heterogeneity and the evolution of polyclonal drug resistance.
Burrell RA; Swanton C
Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
[TBL] [Abstract][Full Text] [Related]
19. Zebrafish as a model to assess cancer heterogeneity, progression and relapse.
Blackburn JS; Langenau DM
Dis Model Mech; 2014 Jul; 7(7):755-62. PubMed ID: 24973745
[TBL] [Abstract][Full Text] [Related]
20. Constraints in cancer evolution.
Venkatesan S; Birkbak NJ; Swanton C
Biochem Soc Trans; 2017 Feb; 45(1):1-13. PubMed ID: 28202655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
